Phio Pharmaceuticals Corp. (PHIO)
CIK 1533040 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 11.6M shares as of Aug 4, 2026 (10-Q).⊙
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Series A Warrants | 11.3M | $2.05 | 24y | — |
| Existing Warants | 5.7M | $2 | — | — |
| Series G Warrants | 2.1M | $3 | — | — |
| Series H Warrants | 1.7M | $3 | — | — |
| Series K Warrants | 1.5M | $2.485 | 2y | — |
| Series I Warrants | 1.2M | $3 | — | — |
| Placement Agent Warrants | 424,739 | $3.75 | — | — |
| Placement Agent Warrants Two | 349,094 | $2.875 | 5y | — |
| Series J Warrants | 318,596 | $2.485 | 5y | — |
| Placement Agent Warrants Three | 71,145 | $3.4188 | 2y | — |
| Common Stock Warrants | 45,750 | $3.75 | — | — |
| Placement Agent Warrants One | 4,500 | $2.8125 | 5y | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 6, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 13.4M underlying shares, as reported Jun 30, 2026 (10-Q).
Reported exercise price: $2.86 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 25.0M = 11.6M O/S + 13.4M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
No convertible-note facts tagged in the 10-Q filed Aug 6, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 11.6M | Aug 4, 2026 |
| + Series A Warrants (if exercised) | 11.3M | Nov 3, 2025 |
| + Existing Warants (if exercised) | 5.7M | Nov 3, 2025 |
| + Series G Warrants (if exercised) | 2.1M | Jan 13, 2025 |
| + Series H Warrants (if exercised) | 1.7M | Jan 14, 2025 |
| + Series K Warrants (if exercised) | 1.5M | Jul 25, 2025 |
| + Series I Warrants (if exercised) | 1.2M | Jan 16, 2025 |
| + Placement Agent Warrants (if exercised) | 424,739 | Nov 3, 2025 |
| + Placement Agent Warrants Two (if exercised) | 349,094 | Nov 3, 2025 |
| + Series J Warrants (if exercised) | 318,596 | Jul 25, 2025 |
| + Placement Agent Warrants Three (if exercised) | 71,145 | Nov 3, 2025 |
| + Common Stock Warrants (if exercised) | 45,750 | Jan 16, 2025 |
| + Placement Agent Warrants One (if exercised) | 4,500 | Nov 3, 2025 |
| Fully diluted estimate | 36.4M | +213.1% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $19.0Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 2 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full PHIO workspace